MADELEINE DUVIC

TitleProfessor
InstitutionMD Anderson
DepartmentDermatology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss FM, Geskin LJ, Schwartz LH, Horwitz SM, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai WZ, Girardi M, Gru A, Guenova E, Hodak E, Hoppe RT, Kempf W, Kim EJ, Lechowicz MJ, Ortiz-Romero PL, Papadavid E, Quaglino P, Pittelkow MR, Prince HM, Sanches JA, Sugaya M, Vermeer MH, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick JJ. Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. Blood. 2021 Nov 10. PMID: 34758074.
      Citations:    Fields:    
    2. Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2021 Oct 12; 12(21):2231. PMID: 34676056.
      Citations:    Fields:    
    3. Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin LJ, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano JM, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Sep 10. PMID: 34507350.
      Citations:    Fields:    
    4. S Mehta R, Torres Cabala CA, DiNardo CD, Daver N, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol. 2021 09 01; 96(9):E350-E353. PMID: 34096089.
      Citations:    Fields:    Translation:Humans
    5. Morse DC, Park KE, Chitsazzadeh V, Li S, Young K, Gunther JR, Dabaja BS, Duvic M. Vulvar Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Int J Gynecol Pathol. 2021 May 01; 40(3):229-233. PMID: 33741766.
      Citations:    Fields:    Translation:HumansCells
    6. Farr MA, Duvic M, Joshi TP. Teledermatology During COVID-19: An Updated Review. Am J Clin Dermatol. 2021 Jul; 22(4):467-475. PMID: 33835345.
      Citations: 5     Fields:    Translation:HumansPHPublic Health
    7. Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer. 2021 05; 148:411-421. PMID: 33794441.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    8. Tran J, Huen A, Duvic M. Renal Cell Carcinoma Associated with Mycosis Fungoides: A Paraneoplastic Syndrome. Case Rep Nephrol. 2020; 2020:8897183. PMID: 33178469.
      Citations:    
    9. Tran J, Duvic M, Torres-Cabala CA. Lymphomatoid Papulosis With a Unique T Follicular Helper-Like Phenotype. Am J Dermatopathol. 2020 Oct; 42(10):776-779. PMID: 32568843.
      Citations:    Fields:    Translation:Humans
    10. Tran J, Vega F, Duvic M. Unmasking a T cell lymphoma: Folliculotropic mycosis fungoides with a gamma-delta phenotype. JAAD Case Rep. 2020 Dec; 6(12):1316-1319. PMID: 32989422.
      Citations:    
    11. Tran J, Morris L, Vu A, Reddy S, Duvic M. Anaphylaxis following administration of extracorporeal photopheresis for cutaneous T cell lymphoma. Dermatol Online J. 2020 Sep 15; 26(9). PMID: 33054950.
      Citations:    Fields:    Translation:Humans
    12. Aung PP, Pemmaraju N, Torres-Cabala CA, Duvic M, Konopleva M, Khoury JD, Prieto VG. Apparent partial loss of CD123 expression in blastic plasmacytoid dendritic cell neoplasm after treatment with CD123-targeted therapy: A novel finding and possible diagnostic pitfall. J Dermatol. 2020 Oct; 47(10):e354-e355. PMID: 32770556.
      Citations:    Fields:    Translation:HumansCells
    13. Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom. 2021 03; 100(2):183-191. PMID: 32667737.
      Citations: 3     Fields:    
    14. Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer. 2020 07; 133:120-130. PMID: 32502876.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    15. Morris L, Tran J, Duvic M. Non-Classic Signs of Sézary Syndrome: A Review. Am J Clin Dermatol. 2020 Jun; 21(3):383-391. PMID: 31953789.
      Citations:    Fields:    Translation:Humans
    16. Zic JA, Ai W, Akilov OE, Carter JB, Duvic M, Foss F, Girardi M, Gru AA, Kim E, Musiek A, Olsen EA, Schieke SM, Shinohara M, Zain JM, Geskin LJ. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. J Am Acad Dermatol. 2020 Aug; 83(2):703-704. PMID: 32305443.
      Citations: 7     Fields:    Translation:HumansCellsPHPublic Health
    17. Ni X, Austin M, Langridge T, Bojaxhi P, Bijani P, Wang X, Duvic M. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma undergoing extracorporeal photopheresis via the CELLEXTM system. Photodermatol Photoimmunol Photomed. 2020 Jul; 36(4):290-298. PMID: 32187738.
      Citations:    Fields:    Translation:HumansCells
    18. Ramachandran V, Park KE, Loya A, Duvic M. Second primary malignancies in blastic plasmacytoid dendritic cell neoplasm: A national database study. J Am Acad Dermatol. 2020 Dec; 83(6):1786-1789. PMID: 32278799.
      Citations: 1     Fields:    Translation:HumansCells
    19. Emge DA, Bassett RL, Duvic M, Huen AO. Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients. Arch Dermatol Res. 2020 May; 312(4):283-288. PMID: 31776647.
      Citations: 3     Fields:    Translation:HumansCells
    20. Ramachandran V, Park KE, Shah JR, Duvic M. Diagnosis of cutaneous T-cell lymphoma by insurance type before and after the Affordable Care Act: a national database study. Dermatol Online J. 2019 Nov 15; 25(11). PMID: 32045145.
      Citations:    Fields:    Translation:Humans
    21. Lewis DJ, Falck BA, Kantrow SM, Pozadzides JV, Hinojosa T, Huang S, Diwan AH, Prieto VG, Duvic M. Necrotizing Granulomatous Dermatitis and Panniculitis Masquerading as T Cell Lymphoma. Skinmed. 2019; 17(6):406-408. PMID: 31904333.
      Citations: 1     Fields:    Translation:Humans
    22. Ying Z, Shiue L, Park K, Kollet J, Bijani P, Goswami M, Duvic M, Ni X. Correction: Blood transcriptional profiling reveals IL-1 and integrin signaling pathways associated with clinical response to extracorporeal photopheresis in patients with leukemic cutaneous T-cell lymphoma. Oncotarget. 2019 Sep 10; 10(52):5492. PMID: 31534633.
      Citations:    Fields:    
    23. Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features. J Cutan Pathol. 2019 Nov; 46(11):872-877. PMID: 31254410.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    24. Ramachandran V, Park KE, Duvic M. Long-term control of mycosis fungoides of the hands with topical bexarotene: an update 15 years later. Int J Dermatol. 2019 Nov; 58(11):e221-e222. PMID: 31209865.
      Citations:    Fields:    Translation:Humans
    25. Kubicki SL, Park KE, Aung PP, Duvic M. Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod J Drugs Dermatol. 2019 May 01; 18(5):460-462. PMID: 31141854.
      Citations: 1     Fields:    Translation:Humans
    26. Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 04 25; 380(17):1628-1637. PMID: 31018069.
      Citations: 56     Fields:    Translation:HumansCellsCTClinical Trials
    27. Park K, Reed J, Talpur R, Duvic M. Nail irregularities associated with Sézary syndrome. Cutis. 2019 Apr; 103(4):E11-E16. PMID: 31116823.
      Citations:    Fields:    Translation:Humans
    28. Méhul B, Ménigot C, Fogel P, Seraidaris A, Genette A, Pascual T, Duvic M, Voegel JJ. Proteomic analysis of stratum corneum in Cutaneous T-Cell Lymphomas and psoriasis. Exp Dermatol. 2019 03; 28(3):317-321. PMID: 30637808.
      Citations: 1     Fields:    Translation:Humans
    29. Welborn M, Duvic M. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Am J Clin Dermatol. 2019 Feb; 20(1):115-122. PMID: 30430444.
      Citations: 2     Fields:    Translation:Humans
    30. An Y, Jiang W, Andraos TY, Reddy JP, Yehia ZA, Lloyd S, Duvic M, D'Souza NM, Milgrom SA, Pinnix CC, Oki Y, Smith GL, Wilson LD, Dabaja BS. Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol. 2019 02; 131:88-92. PMID: 30773193.
      Citations: 2     Fields:    Translation:HumansCells
    31. Kim EJ, Aria AB, Wilmas K, Lewis DJ, Torres-Cabala CA, Nunez C, Dabaja BS, Duvic M. Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation. Pediatr Dermatol. 2019 Jan; 36(1):e23-e26. PMID: 30548331.
      Citations:    Fields:    Translation:HumansCells
    32. Jensen GL, Dabaja BS, Pinnix CC, Gunther JR, Huen A, Duvic M, Oki Y, Fanale M, Hosing C, Milgrom SA. Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. Case Rep Oncol. 2018 Sep-Dec; 11(3):721-728. PMID: 30519174.
      Citations:    
    33. de Jong A, Jabbari A, Dai Z, Xing L, Lee D, Li MM, Duvic M, Hordinsky M, Norris DA, Price V, Mackay-Wiggan J, Clynes R, Christiano AM. High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata. JCI Insight. 2018 10 04; 3(19). PMID: 30282836.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    34. Aria AB, Wilmas K, Kim EJ, Aung PP, Duvic M. The development of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder at the site of a melanoma excision scar. Dermatol Online J. 2018 Sep 15; 24(9). PMID: 30677830.
      Citations: 1     Fields:    Translation:HumansCells
    35. Seto AG, Beatty X, Lynch JM, Hermreck M, Tetzlaff M, Duvic M, Jackson AL. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. Br J Haematol. 2018 11; 183(3):428-444. PMID: 30125933.
      Citations: 62     Fields:    Translation:HumansCells
    36. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 09; 19(9):1192-1204. PMID: 30100375.
      Citations: 81     Fields:    Translation:HumansCTClinical Trials
    37. Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. Am J Surg Pathol. 2018 06; 42(6):726-734. PMID: 29543675.
      Citations: 2     Fields:    Translation:Humans
    38. Lefrançois P, Xie P, Wang L, Tetzlaff MT, Moreau L, Watters AK, Netchiporouk E, Provost N, Gilbert M, Ni X, Sasseville D, Wheeler DA, Duvic M, Litvinov IV. Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients. Oncoimmunology. 2018; 7(8):e1467856. PMID: 30221071.
      Citations: 13     
    39. Korta DZ, Christiano AM, Bergfeld W, Duvic M, Ellison A, Fu J, Harris JE, Hordinsky MK, King B, Kranz D, Mackay-Wiggan J, McMichael A, Norris DA, Price V, Shapiro J, Atanaskova Mesinkovska N. Alopecia areata is a medical disease. J Am Acad Dermatol. 2018 04; 78(4):832-834. PMID: 29548423.
      Citations: 4     Fields:    Translation:Humans
    40. Emge DA, Lewis DJ, Aung PP, Duvic M. Eosinophilic infiltrate resembling eosinophilic cellulitis (Wells syndrome) in a patient with mycosis fungoides. Dermatol Online J. 2018 01 15; 24(1). PMID: 29469767.
      Citations:    Fields:    Translation:Humans
    41. Wohlmuth-Wieser I, Osei JS, Norris D, Price V, Hordinsky MK, Christiano A, Duvic M. Childhood alopecia areata-Data from the National Alopecia Areata Registry. Pediatr Dermatol. 2018 Mar; 35(2):164-169. PMID: 29334143.
      Citations: 2     Fields:    Translation:Humans
    42. Emge DA, Lewis DJ, Aung PP, Duvic M. How to Discern Folliculotropic Mycosis Fungoides From Follicular Mucinosis Using a Pediatric Case. J Cutan Med Surg. 2018 May/Jun; 22(3):336-340. PMID: 29318909.
      Citations: 3     Fields:    Translation:Humans
    43. Mendoza TR, Osei J, Duvic M. The Utility and Validity of the Alopecia Areata Symptom Impact Scale in Measuring Disease-Related Symptoms and their Effect on Functioning. J Investig Dermatol Symp Proc. 2018 01; 19(1):S41-S46. PMID: 29273105.
      Citations: 2     Fields:    Translation:Humans
    44. Huang S, Kim EJ, Lewis DJ, Chan WH, Miranda RN, Duvic M. Mycosis fungoides occurring at the site of previous herpes zoster eruption. Australas J Dermatol. 2018 Aug; 59(3):217-219. PMID: 29280139.
      Citations: 2     Fields:    Translation:Humans
    45. Chan WH, Lewis DJ, Hinojosa T, Curry JL, Duvic M. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation. Pediatr Dermatol. 2018 Jan; 35(1):e13-e16. PMID: 29159918.
      Citations: 1     Fields:    Translation:Humans
    46. Lewis DJ, Holder BB, Duvic M. The "Duvic regimen" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sézary syndrome. Int J Dermatol. 2018 01; 57(1):123-124. PMID: 29152728.
      Citations: 1     Fields:    Translation:HumansCells
    47. Lewis DJ, Dao H, Nagarajan P, Duvic M. Primary cutaneous anaplastic large-cell lymphoma: Complete remission for 13 years after denileukin diftitox. JAAD Case Rep. 2017 Nov; 3(6):501-504. PMID: 29296637.
      Citations: 2     
    48. Jour G, Aung PP, Merrill ED, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Duvic M, Miranda RN, Torres-Cabala CA. Differential expression of CCR4 in primary cutaneous gamma/delta (?/d) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy. J Dermatol Sci. 2018 Jan; 89(1):88-91. PMID: 29030090.
      Citations: 1     Fields:    Translation:HumansCells
    49. Kim EJ, Lewis DJ, Duvic M. Novel Mutations Involving NF-?B and B-Cell Signaling Pathways in Primary Cutaneous Large B-Cell Lymphoma, Leg-Type and Comparison with Sézary Syndrome. J Invest Dermatol. 2017 09; 137(9):1831-1833. PMID: 28843295.
      Citations: 1     Fields:    Translation:HumansCells
    50. Li JY, Lewis DJ, Duvic M. Generalised Eruptive Keratoacanthomas of Grzybowski. J Cutan Med Surg. 2017 Sep/Oct; 21(5):439. PMID: 28920475.
      Citations:    Fields:    Translation:Humans
    51. Lewis DJ, Duvic M. Important considerations for legislation banning commercial tanning beds among minors. Clin Dermatol. 2018 Jan - Feb; 36(1):104-105. PMID: 29241746.
      Citations:    Fields:    Translation:Humans
    52. Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 04; 59(4):880-887. PMID: 28853310.
      Citations: 3     Fields:    Translation:Humans
    53. Winsett FT, Lewis DJ, Duvic M. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. Expert Rev Hematol. 2017 09; 10(9):757-760. PMID: 28756726.
      Citations: 1     Fields:    Translation:Humans
    54. Lewis DJ, Kim EJ, Duvic M. Recent advances in systemic targeted therapy for cutaneous T-cell lymphoma. Expert Opin Pharmacother. 2017 10; 18(14):1535-1536. PMID: 28803489.
      Citations:    Fields:    Translation:Humans
    55. Wilmas K, Wohlmuth-Wieser I, Duvic M. Telangiectasia macularis eruptiva perstans: an old terminology, still frequently used. Dermatol Online J. 2017 Aug 15; 23(8). PMID: 29469737.
      Citations:    Fields:    Translation:Humans
    56. Lewis DJ, Huang S, Duvic M. Oral bexarotene for post-transplant cutaneous T-cell lymphoma. Dermatol Ther. 2017 Sep; 30(5). PMID: 28748653.
      Citations: 1     Fields:    Translation:Humans
    57. Lewis DJ, Duvic M. A possible association between mycosis fungoides and Muir-Torre syndrome: Two disorders with microsatellite instability. JAAD Case Rep. 2017 Jul; 3(4):358-361. PMID: 28761921.
      Citations: 1     
    58. Ni X, Zhang X, Hu CH, Langridge T, Tarapore RS, Allen JE, Oster W, Duvic M. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-?B pathways. Oncotarget. 2017 Sep 22; 8(37):61761-61776. PMID: 28977902.
      Citations: 9     Fields:    
    59. Smith GL, Duvic M, Yehia ZA, Allen P, Garg N, Suki T, Milgrom SA, Pinnix CC, Oki Y, Khoury JD, Dabaja BS. Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):363-369. PMID: 29114604.
      Citations: 2     
    60. Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 08 05; 390(10094):555-566. PMID: 28600132.
      Citations: 95     Fields:    Translation:Humans
    61. Kim EJ, Lewis DJ, Dabaja BS, Duvic M. Curcumin for the treatment of tumor-stage mycosis fungoides. Dermatol Ther. 2017 Jul; 30(4). PMID: 28585397.
      Citations: 2     Fields:    Translation:Humans
    62. Wieser I, Wang C, Alberti-Violetti S, Lyons G, Tran C, Talpur R, Duvic M. Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res. 2017 Aug; 309(6):453-459. PMID: 28516243.
      Citations: 4     Fields:    Translation:Humans
    63. Lewis DJ, Duvic M. Forodesine in the treatment of cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2017 Jun; 26(6):771-775. PMID: 28447489.
      Citations: 1     Fields:    Translation:HumansAnimals
    64. Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RN. Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445. PMID: 28248813.
      Citations:    Fields:    Translation:HumansCells
    65. Lewis DJ, Byekova YA, Emge DA, Duvic M. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series. J Dermatolog Treat. 2017 Sep; 28(6):567-569. PMID: 28635518.
      Citations: 5     Fields:    Translation:Humans
    66. Duvic M, Kim YH, Zinzani PL, Horwitz SM. Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clin Cancer Res. 2017 Jul 15; 23(14):3552-3556. PMID: 28167509.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    67. Guitart J, Martinez-Escala ME, Subtil A, Duvic M, Pulitzer MP, Olsen EA, Kim E, Rook AH, Samimi SS, Wood GS, Girardi M, Junkins-Hopkins J, Ivan DS, Selim MA, Sable KA, Virmani P, Pincus LB, Tetzlaff MT, Kim J, Kim YH. Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. Mod Pathol. 2017 05; 30(5):761-772. PMID: 28128277.
      Citations: 11     Fields:    Translation:HumansCells
    68. Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR, Duvic M, Hwu WJ, Wargo JA, Torres-Cabala CA, Rapini RP, Prieto VG. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176. PMID: 27859479.
      Citations: 35     Fields:    Translation:Humans
    69. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27595880.
      Citations: 2     Fields:    Translation:Humans
    70. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28653029.
      Citations:    
    71. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28712310.
      Citations: 1     Fields:    Translation:Humans
    72. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27550169.
      Citations: 3     Fields:    Translation:HumansCells
    73. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26140234.
      Citations: 11     
    74. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26997441.
      Citations: 6     Fields:    Translation:HumansCells
    75. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26827693.
      Citations: 14     Fields:    Translation:HumansCells
    76. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27637428.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    77. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27247757.
      Citations: 5     
    78. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 24950418.
      Citations: 2     Fields:    Translation:Humans
    79. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25088535.
      Citations: 2     Fields:    Translation:Humans
    80. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25148274.
      Citations:    Fields:    Translation:Humans
    81. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25404094.
      Citations: 54     Fields:    Translation:HumansCTClinical Trials
    82. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 25772268.
      Citations: 6     Fields:    Translation:HumansCells
    83. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26261247.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    84. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26433847.
      Citations: 11     Fields:    Translation:Humans
    85. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26476898.
      Citations: 5     Fields:    Translation:Humans
    86. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 26702474.
      Citations: 10     Fields:    Translation:Humans
    87. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27300436.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    88. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14558406.
      Citations:    Fields:    Translation:Humans
    89. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12399759.
      Citations:    Fields:    Translation:Humans
    90. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12653924.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    91. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12952235.
      Citations:    Fields:    Translation:Humans
    92. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12925230.
      Citations: 3     Fields:    Translation:Humans
    93. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12952756.
      Citations:    Fields:    Translation:Humans
    94. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15289728.
      Citations: 8     Fields:    Translation:HumansCells
    95. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15160932.
      Citations: 1     Fields:    Translation:Humans
    96. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15280837.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    97. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16621887.
      Citations: 24     Fields:    Translation:Humans
    98. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17014481.
      Citations: 14     Fields:    Translation:Humans
    99. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17052486.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    100. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17298107.
      Citations: 3     Fields:    Translation:Humans
    101. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17311990.
      Citations: 45     Fields:    Translation:HumansCTClinical Trials
    102. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17224554.
      Citations: 1     Fields:    Translation:Humans
    103. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18664158.
      Citations: 5     Fields:    Translation:Humans
    104. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18329131.
      Citations: 13     Fields:    Translation:HumansCellsPHPublic Health
    105. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19261011.
      Citations: 19     Fields:    Translation:Humans
    106. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20159328.
      Citations: 12     Fields:    Translation:Humans
    107. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19707308.
      Citations: 12     
    108. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 19874320.
      Citations: 15     Fields:    Translation:HumansCells
    109. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20889234.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    110. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20669795.
      Citations: 1     Fields:    Translation:Humans
    111. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22198560.
      Citations: 10     Fields:    Translation:HumansCells
    112. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22515221.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    113. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22839723.
      Citations: 15     Fields:    Translation:Humans
    114. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22971190.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    115. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23519332.
      Citations: 6     Fields:    Translation:HumansCells
    116. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22981498.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    117. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8240910.
      Citations:    Fields:    Translation:HumansAnimalsCells
    118. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2536762.
      Citations: 1     Fields:    Translation:HumansCells
    119. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1975177.
      Citations: 10     Fields:    Translation:HumansCells
    120. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8682962.
      Citations: 7     Fields:    Translation:HumansCells
    121. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11594571.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    122. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12065565.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    123. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11841632.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    124. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16410787.
      Citations: 26     Fields:    Translation:Humans
    125. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16112357.
      Citations: 7     Fields:    Translation:HumansCells
    126. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16538172.
      Citations: 17     Fields:    Translation:Humans
    127. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21252093.
      Citations: 15     Fields:    Translation:HumansCells
    128. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20596022.
      Citations: 183     Fields:    Translation:HumansCells
    129. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 21868127.
      Citations: 64     Fields:    Translation:Humans
    130. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7615989.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    131. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8006427.
      Citations: 13     Fields:    Translation:Humans
    132. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20826403.
      Citations:    Fields:    Translation:Humans
    133. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1643619.
      Citations: 14     Fields:    Translation:Humans
    134. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8040416.
      Citations: 2     Fields:    Translation:Humans
    135. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9366845.
      Citations:    Fields:    Translation:HumansCells
    136. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11703521.
      Citations: 2     Fields:    Translation:Humans
    137. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11900434.
      Citations: 2     Fields:    Translation:Humans
    138. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12271309.
      Citations:    Fields:    Translation:Humans
    139. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12384439.
      Citations: 16     Fields:    Translation:HumansCells
    140. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 12399756.
      Citations: 12     Fields:    Translation:HumansAnimals
    141. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14632211.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    142. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15743738.
      Citations: 4     Fields:    Translation:HumansCells
    143. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16179379.
      Citations: 11     Fields:    Translation:Humans
    144. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 15756021.
      Citations: 15     Fields:    Translation:HumansCells
    145. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17638852.
      Citations: 52     Fields:    Translation:Humans
    146. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18480841.
      Citations: 11     Fields:    Translation:HumansCells
    147. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18496567.
      Citations: 14     Fields:    Translation:HumansCells
    148. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17884973.
      Citations: 4     Fields:    Translation:HumansCells
    149. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20850703.
      Citations: 7     Fields:    Translation:Humans
    150. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 22850569.
      Citations: 50     Fields:    Translation:Humans
    151. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23868752.
      Citations: 2     Fields:    Translation:Humans
    152. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2230207.
      Citations:    
    153. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3016654.
      Citations: 1     Fields:    Translation:HumansCells
    154. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2041889.
      Citations: 7     Fields:    Translation:Humans
    155. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2380573.
      Citations: 1     Fields:    Translation:HumansCells
    156. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 3668011.
      Citations: 4     Fields:    Translation:Humans
    157. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7712642.
      Citations: 3     Fields:    Translation:Humans
    158. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8188865.
      Citations: 1     Fields:    Translation:Humans
    159. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 8116614.
      Citations: 20     Fields:    Translation:HumansCells
    160. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11346336.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    161. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11242798.
      Citations: 11     Fields:    Translation:HumansCells
    162. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11707858.
      Citations: 1     Fields:    Translation:Humans
    163. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14716770.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    164. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 14686975.
      Citations: 18     Fields:    Translation:Humans
    165. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16231855.
      Citations: 2     Fields:    Translation:Humans
    166. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 16882161.
      Citations: 26     Fields:    Translation:Humans
    167. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 17637820.
      Citations: 12     Fields:    Translation:Humans
    168. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 18501107.
      Citations: 6     Fields:    Translation:Humans
    169. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 20697094.
      Citations: 179     Fields:    Translation:HumansCTClinical Trials
    170. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 23457002.
      Citations: 58     Fields:    Translation:Humans
    171. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1676036.
      Citations: 11     Fields:    Translation:HumansCells
    172. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1476157.
      Citations:    Fields:    Translation:HumansAnimalsCells
    173. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2462349.
      Citations: 7     Fields:    Translation:Humans
    174. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 2568334.
      Citations: 11     Fields:    Translation:HumansCells
    175. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 1358802.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    176. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9024524.
      Citations: 2     Fields:    Translation:Humans
    177. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9462771.
      Citations: 2     Fields:    Translation:HumansCells
    178. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 9684929.
      Citations:    Fields:    Translation:Humans
    179. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 7751471.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    180. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 11115156.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    181. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28421231.
      Citations:    Fields:    Translation:Humans
    182. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29018799.
      Citations: 7     
    183. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28980004.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    184. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28638728.
      Citations: 30     
    185. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29469761.
      Citations:    Fields:    Translation:Humans
    186. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 29892660.
      Citations:    
    187. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 28338261.
      Citations:    Fields:    Translation:Humans
    188. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 27879514.
      Citations: 7     Fields:    Translation:Humans
    189. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 30301395.
      Citations: 1     Fields:    Translation:Humans
    190. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31139332.
      Citations:    Fields:    
    191. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31329384.
      Citations: 1     Fields:    Translation:Humans
    192. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 31782708.
      Citations:    Fields:    Translation:Humans
    193. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 32114498.
      Citations: 8     Fields:    Translation:Humans
    194. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 32621690.
      Citations: 2     Fields:    Translation:Humans
    195. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33158772.
      Citations: 2     Fields:    
    196. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 33604757.
      Citations: 1     Fields:    Translation:Humans
    197. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 34495491.
      Citations:    Fields:    
    198. Zhuang H, Bai J, Chang JY, Yuan Z, Wang P. MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. Oncotarget. 2016 Dec 20; 7(51):84688-84694. PMID: 34543492.
      Citations:    Fields:    
    199. Bassuner J, Miranda RN, Emge DA, DiCicco BA, Lewis DJ, Duvic M. Mycosis Fungoides of the Oral Cavity: Fungating Tumor Successfully Treated with Electron Beam Radiation and Maintenance Bexarotene. Case Rep Dermatol Med. 2016; 2016:5857935. PMID: 28074163.
      Citations: 4     
    200. Messer A, Jenkinson H, Wang W, Duvic M. New B-cell Lymphomas in the Setting of a Previous Rare Breast Implant-Associated B-cell Lymphoma. Plast Reconstr Surg Glob Open. 2016 Nov; 4(11):e1148. PMID: 27975038.
      Citations: 2     
    201. Emge DA, Bassuner J, Lewis DJ, Duvic M. A Rare Case of Mycosis Fungoides in the Oral Cavity and Small Intestine Complicated by Perforation. Case Rep Dermatol. 2016 Sep-Dec; 8(3):294-302. PMID: 27920681.
      Citations: 1     
    202. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 08; 7(45):74380-74392. PMID: 27602582.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    203. Ramani NS, Curry JL, Merrill ED, Aung PP, Prieto V, Tetzlaff MT, Duvic M, Miranda RN, Torres-Cabala C. Primary Cutaneous Gamma-Delta (?/d) T-cell Lymphoma: An Unusual Case With Very Subtle Histopathological Findings. Am J Dermatopathol. 2016 10; 38(10):e147-9. PMID: 27533072.
      Citations:    Fields:    Translation:Humans
    204. Wilmas K, Duvic M, Oki Y. Atypical lymphoproliferative disorder-clinical and pathological features. Dermatol Online J. 2016 Sep 15; 22(9). PMID: 28329608.
      Citations:    Fields:    Translation:Humans
    205. Al-Rohil RN, Torres-Cabala CA, Patel A, Tetzlaff MT, Ivan D, Nagarajan P, Curry JL, Miranda RN, Duvic M, Prieto VG, Aung PP. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 Dec; 43(12):1161-1166. PMID: 27531242.
      Citations: 9     Fields:    Translation:Humans
    206. Min HY, Lee SC, Woo JK, Jung HJ, Park KH, Jeong HM, Hyun SY, Cho J, Lee W, Park JE, Kwon SJ, Lee HJ, Ni X, Shin YK, Johnson FM, Duvic M, Lee HY. Essential Role of DNA Methyltransferase 1-mediated Transcription of Insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors. Clin Cancer Res. 2017 Mar 01; 23(5):1299-1311. PMID: 27582487.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    207. Wieser I, Wohlmuth C, Nunez CA, Duvic M. Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review. Am J Clin Dermatol. 2016 Aug; 17(4):319-27. PMID: 27138554.
      Citations: 3     Fields:    Translation:Humans
    208. Wieser I, Tetzlaff MT, Cabala CA, Duvic M. Primär kutane CD30(+) lymphoproliferative Erkrankungen. J Dtsch Dermatol Ges. 2016 Aug; 14(8):767-84. PMID: 27509410.
      Citations:    Fields:    Translation:Humans
    209. Wieser I, Tetzlaff MT, Torres Cabala CA, Duvic M. Primary cutaneous CD30(+) lymphoproliferative disorders. J Dtsch Dermatol Ges. 2016 Aug; 14(8):767-82. PMID: 27509411.
      Citations: 2     Fields:    Translation:Humans
    210. Wang CM, Nadeem S, Jahan-Tigh RR, Duvic M. Cutaneous T-cell lymphoma in a patient with celiac disease. Cutis. 2016 Jul; 98(1):E1-2. PMID: 27529713.
      Citations:    Fields:    Translation:Humans
    211. Litvinov IV, Shtreis A, Kobayashi K, Glassman S, Tsang M, Woetmann A, Sasseville D, Ødum N, Duvic M. Investigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancy. Oncoimmunology. 2016 Jul; 5(7):e1175799. PMID: 27622024.
      Citations: 8     
    212. Chockalingam R, Duvic M. Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation. Int J Dermatol. 2016 Oct; 55(10):e539-43. PMID: 27207484.
      Citations: 3     Fields:    Translation:Humans
    213. Wang LE, Li C, Xiong P, Gershenwald JE, Prieto VG, Duvic M, Lee JE, Grimm EA, Hsu TC, Wei Q. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7. PMID: 24977319.
      Citations: 1     Fields:    Translation:Humans
    214. Jabbari A, Cerise JE, Chen JC, Mackay-Wiggan J, Duvic M, Price V, Hordinsky M, Norris D, Clynes R, Christiano AM. Molecular signatures define alopecia areata subtypes and transcriptional biomarkers. EBioMedicine. 2016 May; 7:240-7. PMID: 27322477.
      Citations: 18     Fields:    Translation:Humans
    215. Talpur R, Chockalingam R, Wang C, Tetzlaff MT, Duvic M. A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 Feb; 16(2):e15-9. PMID: 26705678.
      Citations: 3     Fields:    Translation:Humans
    216. Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, Xi L, Meng Q, Langridge T, Drummond J, Donehower LA, Doddapaneni H, Muzny DM, Gibbs RA, Wheeler DA, Duvic M. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet. 2015 Dec; 47(12):1426-34. PMID: 26551670.
      Citations: 94     Fields:    Translation:HumansCells
    217. Schlichte MJ, Talpur R, Venkatarajan S, Curry JL, Nagarajan P, Duvic M. Verrucous presentation in patients with mycosis fungoides. Int J Dermatol. 2016 Mar; 55(3):e126-9. PMID: 26519087.
      Citations:    Fields:    Translation:Humans
    218. Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: Treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016 Jan; 74(1):59-67. PMID: 26518172.
      Citations: 11     Fields:    Translation:Humans
    219. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, Foss F, Girardi M, Bagot M, Michel L, Battistella M, Guitart J, Kuzel TM, Martinez-Escala ME, Estrach T, Papadavid E, Antoniou C, Rigopoulos D, Nikolaou V, Sugaya M, Miyagaki T, Gniadecki R, Sanches JA, Cury-Martins J, Miyashiro D, Servitje O, Muniesa C, Berti E, Onida F, Corti L, Hodak E, Amitay-Laish I, Ortiz-Romero PL, Rodríguez-Peralto JL, Knobler R, Porkert S, Bauer W, Pimpinelli N, Grandi V, Cowan R, Rook A, Kim E, Pileri A, Patrizi A, Pujol RM, Wong H, Tyler K, Stranzenbach R, Querfeld C, Fava P, Maule M, Willemze R, Evison F, Morris S, Twigger R, Talpur R, Kim J, Ognibene G, Li S, Tavallaee M, Hoppe RT, Duvic M, Whittaker SJ, Kim YH. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. J Clin Oncol. 2015 Nov 10; 33(32):3766-73. PMID: 26438120.
      Citations: 69     Fields:    Translation:Humans
    220. Oh CW, Ivan D, Curry JL, Ellis R, Gerber H, Duvic M, Torres-Cabala C. A case of indeterminate dendritic cell tumor presenting with leonine facies. J Cutan Pathol. 2016 Feb; 43(2):158-63. PMID: 26272726.
      Citations: 1     Fields:    Translation:HumansCells
    221. Wang C, Reusser N, Shelton M, Reed J, Doan H, Torres-Cabala CA, Dabaja B, Duvic M. An unusual case of cytotoxic peripheral T-cell lymphoma. JAAD Case Rep. 2015 Sep; 1(5):257-60. PMID: 27051746.
      Citations:    
    222. Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D, Duvic M. Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries. Cancer Med. 2015 Sep; 4(9):1440-7. PMID: 26136403.
      Citations: 13     Fields:    Translation:HumansPHPublic Health
    223. Wang C, Tetzlaff M, Hick R, Duvic M. Reed syndrome presenting with leiomyosarcoma. JAAD Case Rep. 2015 May; 1(3):150-2. PMID: 27051714.
      Citations: 3     
    224. Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma. 2015; 56(10):2847-54. PMID: 25791237.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    225. Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3e recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 2015 Jun; 100(6):794-800. PMID: 25795722.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    226. Alberti-Violetti S, Talpur R, Schlichte M, Sui D, Duvic M. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):e105-12. PMID: 25817937.
      Citations: 11     Fields:    Translation:Humans
    227. Litvinov IV, Tetzlaff MT, Rahme E, Habel Y, Risser DR, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M. Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries. Cancer. 2015 Jun 15; 121(12):1993-2003. PMID: 25728286.
      Citations: 19     Fields:    Translation:Humans
    228. Herrmann JL, Syklawer E, Tarrillion M, Duvic M, Hughey LC. Concomitant mycosis fungoides and vitiligo: how mycosis fungoides may contribute to melanocyte destruction. Dermatology. 2015; 230(2):143-9. PMID: 25634551.
      Citations: 1     Fields:    Translation:HumansCells
    229. Duvic M, Pinter-Brown LC, Foss FM, Sokol L, Jorgensen JL, Challagundla P, Dwyer KM, Zhang X, Kurman MR, Ballerini R, Liu L, Kim YH. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015 Mar 19; 125(12):1883-9. PMID: 25605368.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    230. Duvic M. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Hematology Am Soc Hematol Educ Program. 2015; 2015:529-44. PMID: 26637769.
      Citations: 6     Fields:    Translation:Humans
    231. de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MT. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69. PMID: 25666664.
      Citations: 4     Fields:    Translation:HumansCells
    232. Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes J. Characteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):358-363. PMID: 25630528.
      Citations: 12     Fields:    Translation:HumansCells
    233. Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015 Feb; 72(2):286-92. PMID: 25476993.
      Citations: 34     Fields:    Translation:Humans
    234. Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, Armstrong PA, Liu P, Duvic M. Vitamin D deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):518-24. PMID: 25442486.
      Citations: 8     Fields:    Translation:Humans
    235. Kash N, Vin H, Danialan R, Prieto VG, Duvic M. Stenotrophomonas maltophilia with histopathological features mimicking cutaneous gamma/delta T-cell lymphoma. Int J Infect Dis. 2015 Jan; 30:7-9. PMID: 25462188.
      Citations: 2     Fields:    Translation:HumansCells
    236. Ni X, Jorgensen JL, Goswami M, Challagundla P, Decker WK, Kim YH, Duvic MA. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome. Clin Cancer Res. 2015 Jan 15; 21(2):274-85. PMID: 25376389.
      Citations: 49     Fields:    Translation:HumansCells
    237. Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):e83-93. PMID: 25458083.
      Citations: 9     Fields:    Translation:Humans
    238. Kyvernitakis A, Duvic M, Mahale P, Torres HA. Interferon-based treatment for patients with mycosis fungoides and hepatitis C virus infection: a case series. Am J Clin Dermatol. 2014 Oct; 15(5):451-6. PMID: 24934807.
      Citations: 1     Fields:    Translation:Humans
    239. Boulos S, Vaid R, Aladily TN, Ivan DS, Talpur R, Duvic M. Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: a case series of 34 patients. J Am Acad Dermatol. 2014 Dec; 71(6):1117-26. PMID: 25264240.
      Citations: 6     Fields:    Translation:Humans
    240. Applebaum DS, Daulat S, Duvic M. Multiple skin-colored papules with diffuse sclerosis. JAMA Dermatol. 2014 Aug; 150(8):893-4. PMID: 24919716.
      Citations:    Fields:    Translation:Humans
    241. Talpur R, Venkatarajan S, Duvic M. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma. Expert Rev Clin Pharmacol. 2014 Sep; 7(5):591-7. PMID: 25068889.
      Citations: 3     Fields:    Translation:Humans
    242. Rangwala S, Duvic M. Antinuclear antibody seropositivity in men with cutaneous B-cell lymphoma of the scalp. Skinmed. 2014 Jul-Aug; 12(4):244-8. PMID: 25335355.
      Citations:    Fields:    Translation:Humans
    243. Gera S, Dekmezian MS, Duvic M, Tschen JA, Vega F, Cho-Vega JH. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement. Am J Dermatopathol. 2014 Mar; 36(3):244-51. PMID: 24247574.
      Citations: 4     Fields:    Translation:HumansCells
    244. Dreno B, Urosevic-Maiwald M, Kim Y, Guitart J, Duvic M, Dereure O, Khammari A, Knol AC, Derbij A, Lusky M, Didillon I, Santoni AM, Acres B, Bataille V, Chenard MP, Bleuzen P, Limacher JM, Dummer R. TG1042 (Adenovirus-interferon-?) in primary cutaneous B-cell lymphomas: a phase II clinical trial. PLoS One. 2014; 9(2):e83670. PMID: 24586226.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    245. Singh L, Boulavsky JL, Duvic M. Concurrent chronic lymphocytic leukemia and cutaneous T cell lymphoma: a case series. Leuk Lymphoma. 2014 Sep; 55(9):2192-5. PMID: 24313830.
      Citations:    Fields:    Translation:Humans
    246. Talpur R, Thompson A, Gangar P, Duvic M. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):297-304. PMID: 24589156.
      Citations: 4     Fields:    Translation:Humans
    247. Nadeem S, Hymes S, Kebriaei P, Abruzzo L, Curry JL, Duvic M. Alopecia areata after HLA-identical BMT from an affected, sibling donor. Bone Marrow Transplant. 2014 Apr; 49(4):592-4. PMID: 24442249.
      Citations: 1     Fields:    Translation:Humans
    248. Netchiporouk E, Litvinov IV, Moreau L, Gilbert M, Sasseville D, Duvic M. Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle. 2014; 13(21):3331-5. PMID: 25485578.
      Citations: 37     Translation:HumansCells
    249. Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, Torres-Cabala CA, Duvic M, Prieto VG, Tsai KY, Curry JL. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma. J Cutan Pathol. 2014 Mar; 41(3):326-8. PMID: 24372055.
      Citations: 5     Fields:    Translation:Humans
    250. Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, Kuzel TM. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014 Feb 20; 123(8):1159-66. PMID: 24335103.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    251. Mendoza TR, Osei JS, Shi Q, Duvic M. Development of the alopecia areata symptom impact scale. J Investig Dermatol Symp Proc. 2013 Dec; 16(1):S51-2. PMID: 24326557.
      Citations: 6     Fields:    Translation:Humans
    252. Shi Q, Duvic M, Osei JS, Hordinsky MK, Norris DA, Price VH, Amos CI, Christiano AM, Mendoza TR. Health-Related Quality of Life (HRQoL) in alopecia areata patients-a secondary analysis of the National Alopecia Areata Registry Data. J Investig Dermatol Symp Proc. 2013 Dec; 16(1):S49-50. PMID: 24326555.
      Citations: 10     Fields:    Translation:Humans
    253. Duvic M, Christiano AM, Hordinsky MK, Norris DA, Price VH, Amos CI. The national alopecia areata registry-update. J Investig Dermatol Symp Proc. 2013 Dec; 16(1):S53. PMID: 24326558.
      Citations:    Fields:    Translation:Humans
    254. Straus DJ, Duvic M, Horwitz SM, Hymes K, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski PL. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Ann Oncol. 2014 Jan; 25(1):206-10. PMID: 24285015.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    255. Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CA. Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol. 2014 Jan; 41(1):51-7. PMID: 24151865.
      Citations: 2     Fields:    Translation:Humans
    256. Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife. 2013 Nov 05; 2:e00969. PMID: 24192036.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    257. McQuitty E, Curry JL, Tetzlaff MT, Prieto VG, Duvic M, Torres-Cabala C. The differential diagnosis of CD8-positive ("type D") lymphomatoid papulosis. J Cutan Pathol. 2014 Feb; 41(2):88-100. PMID: 24118002.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    258. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther. 2014 Jan; 13(1):221-9. PMID: 24170769.
      Citations: 12     Fields:    Translation:HumansCells
    259. Curry JL, Torres-Cabala CA, Kim KB, Tetzlaff MT, Duvic M, Tsai KY, Hong DS, Prieto VG. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84. PMID: 23879247.
      Citations: 15     Fields:    Translation:HumansCells
    260. Seyfer SJ, Duvic M. Disappearance of seborrheic keratoses following treatment with methotrexate. Cutis. 2013 Jul; 92(1):E2-3. PMID: 23961531.
      Citations: 1     Fields:    Translation:Humans
    261. Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):377-84. PMID: 23770157.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    262. Benton EC, Crichton S, Talpur R, Agar NS, Fields PA, Wedgeworth E, Mitchell TJ, Cox M, Ferreira S, Liu P, Robson A, Calonje E, Stefanato CM, Wilkins B, Scarisbrick J, Wain EM, Child F, Morris S, Duvic M, Whittaker SJ. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013 Sep; 49(13):2859-68. PMID: 23735705.
      Citations: 19     Fields:    Translation:Humans
    263. Wang CM, Duvic M, Dabaja BS. Acral erosive mycosis fungoides: successful treatment with localised radiotherapy. BMJ Case Rep. 2013 Apr 16; 2013. PMID: 23595169.
      Citations: 1     Fields:    Translation:Humans
    264. Kim S, Jahan-Tigh R, Duvic M. Papuloerythroderma of Ofuji associated with an indolent CD3(-), CD4(+), TCR(-) peripheral T-cell lymphoma. Leuk Lymphoma. 2013 Sep; 54(9):2059-61. PMID: 23294328.
      Citations:    Fields:    Translation:HumansCells
    265. Kim S, Diaz LZ, Duvic M. Primary cutaneous follicle center lymphoma following deep brain stimulation implants. Leuk Lymphoma. 2013 Aug; 54(8):1806-7. PMID: 23294327.
      Citations:    Fields:    Translation:Humans
    266. Curry JL, Falchook GS, Hwu WJ, Torres-Cabala CA, Duvic M, Tetzlaff MT, Prieto VG. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Am J Dermatopathol. 2013 Feb; 35(1):125-8. PMID: 22878367.
      Citations: 1     Fields:    Translation:Humans
    267. Lessin SR, Duvic M, Guitart J, Pandya AG, Strober BE, Olsen EA, Hull CM, Knobler EH, Rook AH, Kim EJ, Naylor MF, Adelson DM, Kimball AB, Wood GS, Sundram U, Wu H, Kim YH. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013 Jan; 149(1):25-32. PMID: 23069814.
      Citations: 23     Fields:    Translation:Humans
    268. Guitart J, Weisenburger DD, Subtil A, Kim E, Wood G, Duvic M, Olsen E, Junkins-Hopkins J, Rosen S, Sundram U, Ivan D, Selim MA, Pincus L, Deonizio JM, Kwasny M, Kim YH. Cutaneous ?d T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012 Nov; 36(11):1656-65. PMID: 23073324.
      Citations: 24     Fields:    Translation:HumansCells
    269. Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol. 2012 Oct; 51(10):1195-8. PMID: 22994666.
      Citations: 4     Fields:    Translation:Humans
    270. Paul LJ, Duvic M. Mycosis fungoides following skin trauma. J Am Acad Dermatol. 2012 Oct; 67(4):e148. PMID: 22980272.
      Citations: 4     Fields:    Translation:HumansCells
    271. Prince HM, Martin AG, Olsen EA, Fivenson DP, Duvic M. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma. 2013 Jan; 54(1):69-75. PMID: 22738414.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    272. Jahan-Tigh RR, Huen AO, Lee GL, Pozadzides JV, Liu P, Duvic M. Hydrochlorothiazide and cutaneous T cell lymphoma: prospective analysis and case series. Cancer. 2013 Feb 15; 119(4):825-31. PMID: 22952039.
      Citations: 14     Fields:    Translation:Humans
    273. Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM. Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma. 2013 Mar; 54(3):514-9. PMID: 22891708.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    274. Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol. 2012 Aug; 51(8):930-4. PMID: 22788808.
      Citations: 12     Fields:    Translation:Humans
    275. Nicholson KM, Patel KP, Duvic M, Prieto VG, Tetzlaff MT. Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol. 2012 Sep; 39(9):866-71. PMID: 22809282.
      Citations:    Fields:    Translation:HumansCells
    276. Alexander LJ, Paravar T, Duvic M, Prieto V, Hymes SR. Annular plaques: An unusual manifestation of graft-versus-host disease. Dermatol Online J. 2012 Jun 15; 18(6):4. PMID: 22747928.
      Citations: 1     Fields:    Translation:Humans
    277. Talpur R, Duvic M. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2012 Jun; 12(3):180-5. PMID: 22521504.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    278. Garcia-Uribe A, Zou J, Duvic M, Cho-Vega JH, Prieto VG, Wang LV. In vivo diagnosis of melanoma and nonmelanoma skin cancer using oblique incidence diffuse reflectance spectrometry. Cancer Res. 2012 Jun 01; 72(11):2738-45. PMID: 22491533.
      Citations: 17     Fields:    Translation:Humans
    279. Horwitz SM, Kim YH, Foss F, Zain JM, Myskowski PL, Lechowicz MJ, Fisher DC, Shustov AR, Bartlett NL, Delioukina ML, Koutsoukos T, Saunders ME, O'Connor OA, Duvic M. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012 May 03; 119(18):4115-22. PMID: 22394596.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    280. Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem. 2012 Mar; 4(4):471-86. PMID: 22416775.
      Citations: 26     Fields:    Translation:Humans
    281. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Straus DJ. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. J Am Acad Dermatol. 2012 Nov; 67(5):867-75. PMID: 22285675.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    282. Shiue LH, Ni X, Prieto VG, Jorgensen JL, Curry JL, Goswami M, Sweeney SA, Duvic M. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol. 2013 Sep; 52(9):1111-4. PMID: 22257096.
      Citations: 3     Fields:    Translation:HumansCells
    283. Falchook GS, Duvic M, Hong DS, Wheler J, Naing A, Lim J, Kurzrock R. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. Cancer Chemother Pharmacol. 2012 May; 69(5):1117-26. PMID: 22205203.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    284. Duvic M. CD30+ neoplasms of the skin. Curr Hematol Malig Rep. 2011 Dec; 6(4):245-50. PMID: 21850406.
      Citations: 6     Fields:    Translation:Humans
    285. Williams VL, Torres-Cabala CA, Duvic M. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol. 2011 Dec 01; 12(6):389-401. PMID: 21863906.
      Citations: 6     Fields:    Translation:HumansCells
    286. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011 Oct 13; 118(15):4024-35. PMID: 21841159.
      Citations: 60     Fields:    Translation:Humans
    287. Holcomb M, Duvic M, Cutlan J. Erythema gyratum repens-like eruptions with large cell transformation in a patient with mycosis fungoides. Int J Dermatol. 2012 Oct; 51(10):1231-3. PMID: 21726213.
      Citations:    Fields:    Translation:Humans
    288. Foss F, Duvic M, Olsen EA. Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma. Am J Hematol. 2011 Jul; 86(7):627-30. PMID: 21674574.
      Citations: 3     Fields:    
    289. Querfeld C, Kuzel TM, Kim YH, Porcu P, Duvic M, Musiek A, Rook AH, Mark LA, Pinter-Brown L, Hamid O, Lin B, Bian Y, Boye M, Day JM, Rosen ST. Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. Leuk Lymphoma. 2011 Aug; 52(8):1474-80. PMID: 21649541.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    290. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011 Jun 20; 29(18):2598-607. PMID: 21576639.
      Citations: 112     Fields:    Translation:Humans
    291. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11(3):286-8. PMID: 21658657.
      Citations: 4     Fields:    Translation:Humans
    292. Talpur R, Demierre MF, Geskin L, Baron E, Pugliese S, Eubank K, Zic JA, Miller DR, Tharp M, Bohjanen K, Duvic M. Multicenter photopheresis intervention trial in early-stage mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):219-27. PMID: 21575927.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    293. Ni X, Duvic M. Dendritic cells and cutaneous T-cell lymphomas. G Ital Dermatol Venereol. 2011 Apr; 146(2):103-13. PMID: 21505396.
      Citations: 5     Fields:    Translation:HumansCells
    294. Curry JL, Prieto VG, Jones DM, Vega F, Duvic M, Diwan AH. Transient iatrogenic immunodeficiency-related B-cell lymphoproliferative disorder of the skin in a patient with mycosis fungoides/Sézary syndrome. J Cutan Pathol. 2011 Mar; 38(3):295-7. PMID: 19889052.
      Citations: 2     Fields:    Translation:HumansCells
    295. Garcia-Uribe A, Smith EB, Zou J, Duvic M, Prieto V, Wang LV. In-vivo characterization of optical properties of pigmented skin lesions including melanoma using oblique incidence diffuse reflectance spectrometry. J Biomed Opt. 2011 Feb; 16(2):020501. PMID: 21361657.
      Citations: 14     Fields:    Translation:Humans
    296. Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre MF, Pittelkow M, Wilson LD, Pinter-Brown L, Advani R, Parker S, Kim EJ, Junkins-Hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol. 2011 Feb; 64(2):352-404. PMID: 21145619.
      Citations: 25     Fields:    Translation:Humans
    297. Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, Rook AH. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol. 2010 Dec; 63(6):975-83. PMID: 20888065.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    298. Horwitz SM, Duvic M, Hsi ED. Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides. Clin Adv Hematol Oncol. 2010 Dec; 8(12):1-15. PMID: 21344783.
      Citations:    Fields:    Translation:Humans
    299. Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2010 Dec 15; 102(24):1835-44. PMID: 21115882.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    300. Bi MY, Curry JL, Christiano AM, Hordinsky MK, Norris DA, Price VH, Duvic M. The spectrum of hair loss in patients with mycosis fungoides and Sézary syndrome. J Am Acad Dermatol. 2011 Jan; 64(1):53-63. PMID: 21036417.
      Citations: 6     Fields:    Translation:Humans
    301. Wang LE, Huang YJ, Yin M, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15. PMID: 20655738.
      Citations: 4     Fields:    Translation:Humans
    302. Patel P, Talpur R, Duvic M. Langerhans cell histiocytosis arising from a BCC: a case report and review of the literature. Cutis. 2010 Jun; 85(6):295-300. PMID: 20666189.
      Citations:    Fields:    Translation:HumansCells
    303. Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol. 2010 Aug; 130(8):2110-9. PMID: 20393484.
      Citations: 37     Fields:    Translation:HumansCells
    304. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010 May 10; 28(14):2365-72. PMID: 20351328.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    305. Khan O, Fotheringham S, Wood V, Stimson L, Zhang C, Pezzella F, Duvic M, Kerr DJ, La Thangue NB. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A. 2010 Apr 06; 107(14):6532-7. PMID: 20308564.
      Citations: 56     Fields:    Translation:HumansCells
    306. Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010 Apr 10; 28(11):1870-7. PMID: 20212249.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    307. Richmond HM, Duvic M, Macfarlane DF. Primary and metastatic malignant tumors of the scalp: an update. Am J Clin Dermatol. 2010; 11(4):233-46. PMID: 20509718.
      Citations: 3     Fields:    Translation:Humans
    308. Duvic M, Olsen EA, Breneman D, Pacheco TR, Parker S, Vonderheid EC, Abuav R, Ricker JL, Rizvi S, Chen C, Boileau K, Gunchenko A, Sanz-Rodriguez C, Geskin LJ. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2009 Dec; 9(6):412-6. PMID: 19951879.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    309. Mukherjee N, Morrell DS, Duvic M, Stewart PW, Goldsmith LA. Attitudes of dermatologists in the southeastern United States regarding treatment of alopecia areata: a cross-sectional survey study. BMC Dermatol. 2009 Nov 12; 9:11. PMID: 19909522.
      Citations:    Fields:    Translation:Humans
    310. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009 Oct 01; 15(19):6217-24. PMID: 19789316.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    311. Terushkin V, Dusza SW, Mullani NA, Duvic M, Zouridakis G, Weinstock M, Drugge R, Prieto VG, Dhawan A, Terry C, Talpur R, Marghoob AA. Transillumination as a means to differentiate melanocytic lesions based on their vascularity. Arch Dermatol. 2009 Sep; 145(9):1060-2. PMID: 19770455.
      Citations: 2     Fields:    Translation:Humans
    312. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol. 2009 Oct; 61(4):592.e1-9. PMID: 19682769.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    313. Barahmani N, Schabath MB, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009 Oct; 61(4):581-91. PMID: 19608295.
      Citations: 36     Fields:    Translation:Humans
    314. Vidulich KA, Rady PL, He Q, Tyring SK, Duvic M. Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. Int J Dermatol. 2009 Jun; 48(6):598-602. PMID: 19538368.
      Citations: 2     Fields:    Translation:HumansCells
    315. Adeniran AJ, Prieto VG, Chon S, Duvic M, Diwan AH. Atypical histologic and immunohistochemical findings in melanocytic nevi after liquid nitrogen cryotherapy. J Am Acad Dermatol. 2009 Aug; 61(2):341-5. PMID: 19362750.
      Citations: 1     Fields:    Translation:Humans
    316. Chandra P, Plaza JA, Zuo Z, Diwan AH, Koeppen H, Duvic M, Medeiros LJ, Prieto VG. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. Am J Clin Pathol. 2009 Apr; 131(4):511-5. PMID: 19289586.
      Citations: 5     Fields:    Translation:Humans
    317. Talpur R, Cox K, Duvic M. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb; 5(2):195-210. PMID: 20213916.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    318. Kunishige JH, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009 Jul; 34(5):576-81. PMID: 19196298.
      Citations: 16     Fields:    Translation:Humans
    319. Eubank KV, Nash J, Duvic M. Sweet syndrome associated with celiac disease. Am J Clin Dermatol. 2009; 10(5):343-5. PMID: 19658449.
      Citations: 1     Fields:    Translation:Humans
    320. Hicks LD, Duvic M. Wiskott-Aldrich syndrome and molluscum contagiosum: a therapeutic challenge after reaction to cidofovir. Int J Dermatol. 2008 Dec; 47(12):1304-5. PMID: 19126022.
      Citations:    Fields:    Translation:Humans
    321. Li C, Zhao H, Hu Z, Liu Z, Wang LE, Gershenwald JE, Prieto VG, Lee JE, Duvic M, Grimm EA, Wei Q. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51. PMID: 18563783.
      Citations: 24     Fields:    Translation:Humans
    322. Sun G, Berthelot C, Li Y, Glass DA, George D, Pandya A, Kurzrock R, Duvic M. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol. 2009 Feb; 60(2):231-5. PMID: 19026464.
      Citations: 17     Fields:    Translation:Humans
    323. Duvic M, Talpur R. Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug; 4(4):457-69. PMID: 18684057.
      Citations: 13     Fields:    Translation:HumansCells
    324. Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol. 2008 Aug; 59(2 Suppl 1):S16-22. PMID: 18625371.
      Citations: 3     Fields:    Translation:Humans
    325. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008 Jul; 159(1):105-12. PMID: 18489588.
      Citations: 33     Fields:    Translation:HumansCells
    326. Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L, Dummer R, Duvic M, Hoppe RT, Pimpinelli N, Rosen ST, Vermeer MH, Whittaker S, Willemze R. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008 Sep 01; 112(5):1600-9. PMID: 18567836.
      Citations: 60     Fields:    Translation:Humans
    327. Ahmed AM, Barahmani N, Duvic M. Familial alopecia areata and chronic thrombocytopenia. J Am Acad Dermatol. 2008 May; 58(5 Suppl 1):S75-7. PMID: 18489053.
      Citations: 3     Fields:    Translation:Humans
    328. Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84. PMID: 18183598.
      Citations: 25     Fields:    Translation:Humans
    329. Brownell I, Etzel CJ, Yang DJ, Taylor SH, Duvic M. Increased malignancy risk in the cutaneous T-cell lymphoma patient population. Clin Lymphoma Myeloma. 2008 Apr; 8(2):100-5. PMID: 18501103.
      Citations: 9     Fields:    Translation:Humans
    330. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008 Apr; 6(4):436-42. PMID: 18433609.
      Citations: 24     Fields:    Translation:Humans
    331. Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr; 6(4):356-421. PMID: 18433606.
      Citations: 1     Fields:    Translation:Humans
    332. Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J, Keating MJ. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis. 2008 Apr 01; 46(7):e69-71. PMID: 18444808.
      Citations: 2     Fields:    Translation:HumansCells
    333. Sun G, Berthelot C, Duvic M. A second case of dermatitis herpetiformis and cutaneous T-cell lymphoma. Clin Exp Dermatol. 2008 Jul; 33(4):506-7. PMID: 18346181.
      Citations:    Fields:    Translation:Humans
    334. Awar O, Duvic M. Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine. Oncology. 2007; 73(1-2):130-5. PMID: 18337626.
      Citations: 1     Fields:    Translation:Humans
    335. Leitenberger JJ, Berthelot CN, Polder KD, Pro B, McLaughlin P, Jones D, Duvic M. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008 Mar; 58(3):480-4. PMID: 18280345.
      Citations: 11     Fields:    Translation:HumansCells
    336. Cen P, Duvic M, Cohen PR, Kurzrock R. Increased cancer antigen 27.29 (CA27.29) level in patients with mycosis fungoides. J Am Acad Dermatol. 2008 Mar; 58(3):382-6. PMID: 18280334.
      Citations:    Fields:    Translation:HumansCells
    337. Vidulich K, Jones D, Duvic M. Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox. Clin Lymphoma Myeloma. 2008 Feb; 8(1):55-8. PMID: 18501089.
      Citations: 3     Fields:    Translation:Humans
    338. Duvic M. EGFR inhibitor-associated acneiform folliculitis: assessment and management. Am J Clin Dermatol. 2008; 9(5):285-94. PMID: 18717603.
      Citations: 6     Fields:    Translation:Humans
    339. Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S21-8. PMID: 18086343.
      Citations: 10     Fields:    Translation:Humans
    340. Li C, Chen K, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8. PMID: 18049450.
      Citations: 10     Fields:    Translation:HumansCells
    341. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res. 2007 Nov 01; 13(21):6532-9. PMID: 17975167.
      Citations: 20     Fields:    Translation:HumansCells
    342. Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc). 2007 Sep; 43(9):585-99. PMID: 17940636.
      Citations: 14     Fields:    Translation:HumansAnimals
    343. Setyadi HG, Nash JW, Duvic M. The solitary lymphomatous papule, nodule, or tumor. J Am Acad Dermatol. 2007 Dec; 57(6):1072-83. PMID: 17706321.
      Citations: 1     Fields:    Translation:Humans
    344. Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs. 2007 Jul; 16(7):1111-20. PMID: 17594194.
      Citations: 110     Fields:    Translation:HumansAnimals
    345. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007 Jul 20; 25(21):3109-15. PMID: 17577020.
      Citations: 306     Fields:    Translation:HumansCTClinical Trials
    346. Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol. 2007 Sep; 157(3):433-40. PMID: 17553039.
      Citations: 33     Fields:    Translation:Humans
    347. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo MG, Sterry W, Laroche L, Trautinger F, Whittaker S. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007 Sep 15; 110(6):1713-22. PMID: 17540844.
      Citations: 226     Fields:    Translation:Humans
    348. Straus DJ, Duvic M, Kuzel T, Horwitz S, Demierre MF, Myskowski P, Steckel S. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007 May 01; 109(9):1799-803. PMID: 17366595.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    349. Doherty SD, Giancola A, Nash J, Lazar A, Duvic M. Papulo-vesicular eruption. Dermatol Online J. 2007 May 01; 13(2):24. PMID: 17498443.
      Citations:    Fields:    Translation:Humans
    350. Baser S, Onn A, Lin E, Morice RC, Duvic M. Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer. 2007 Apr 15; 109(8):1550-5. PMID: 17351938.
      Citations: 5     Fields:    Translation:Humans
    351. Li C, Hu Z, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8. PMID: 17328085.
      Citations: 5     Fields:    Translation:Humans
    352. Lozano A, Duvic M. Cutaneous T-cell lymphoma in non-blood-related family members: report of an additional case. J Am Acad Dermatol. 2007 Mar; 56(3):521. PMID: 17317497.
      Citations: 4     Fields:    Translation:Humans
    353. May SA, Jones D, Medeiros LJ, Duvic M, Prieto VG, Lazar AJ. Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients. Am J Dermatopathol. 2007 Feb; 29(1):62-7. PMID: 17284964.
      Citations: 5     Fields:    Translation:HumansCells
    354. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park). 2007 Feb; 21(2 Suppl 1):33-40. PMID: 17474358.
      Citations: 1     Fields:    Translation:Humans
    355. Martinez-Mir A, Zlotogorski A, Gordon D, Petukhova L, Mo J, Gilliam TC, Londono D, Haynes C, Ott J, Hordinsky M, Nanova K, Norris D, Price V, Duvic M, Christiano AM. Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet. 2007 Feb; 80(2):316-28. PMID: 17236136.
      Citations: 36     Fields:    Translation:HumansCells
    356. Vidulich KA, Donley SE, Duvic M. Multinodular cutaneous spread in neuroendocrine tumor of the breast : an unusual presentation. Am J Clin Dermatol. 2007; 8(6):379-83. PMID: 18039021.
      Citations: 4     Fields:    Translation:Humans
    357. Vu J, Wallace GR, Singh R, Diwan H, Prieto V, Rady P, Tyring S, Duvic M. Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol. 2007; 8(5):307-10. PMID: 17902733.
      Citations:    Fields:    Translation:HumansCells
    358. Hultgren TL, Jones D, Duvic M. Topical nitrogen mustard for the treatment of granulomatous slack skin. Am J Clin Dermatol. 2007; 8(1):51-4. PMID: 17298108.
      Citations: 1     Fields:    Translation:Humans
    359. Doherty SD, George S, Prieto VG, Gershenwald JE, Duvic M. Segmental neurofibromatosis in association with a large congenital nevus and malignant melanoma. Dermatol Online J. 2006 Dec 10; 12(7):22. PMID: 17459308.
      Citations: 1     Fields:    Translation:Humans
    360. Li C, Hu Z, Liu Z, Wang LE, Strom SS, Gershenwald JE, Lee JE, Ross MI, Mansfield PF, Cormier JN, Prieto VG, Duvic M, Grimm EA, Wei Q. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32. PMID: 17164380.
      Citations: 34     Fields:    Translation:HumansCells
    361. Doherty SD, Prieto VG, George S, Hazarika P, Duvic M. High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. Melanoma Res. 2006 Oct; 16(5):461-3. PMID: 17013097.
      Citations: 15     Fields:    Translation:Humans
    362. Doherty SD, Ni X, Doherty CB, Jones D, Zhao X, Owen LB, Duvic M. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions. Arch Dermatol Res. 2006 Dec; 298(7):353-6. PMID: 17021762.
      Citations: 4     Fields:    Translation:HumansCells
    363. Li C, Liu Z, Zhang Z, Strom SS, Gershenwald JE, Prieto VG, Lee JE, Ross MI, Mansfield PF, Cormier JN, Duvic M, Grimm EA, Wei Q. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80. PMID: 16990805.
      Citations: 19     Fields:    Translation:Humans
    364. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 01; 109(1):31-9. PMID: 16960145.
      Citations: 347     Fields:    Translation:HumansCellsCTClinical Trials
    365. Poonawalla T, Diwan H, Duvic M. Mycosis fungoides with coccidioidomycosis. Clin Lymphoma Myeloma. 2006 Sep; 7(2):148-50. PMID: 17026828.
      Citations: 2     Fields:    Translation:HumansAnimals
    366. Duvic M. Photopheresis versus transimmunization? Leuk Lymphoma. 2006 Aug; 47(8):1449. PMID: 16966250.
      Citations: 1     Fields:    Translation:Humans
    367. Wang LE, Hsu TC, Xiong P, Strom SS, Duvic M, Clayman GL, Weber RS, Lippman SM, Goldberg LH, Wei Q. 4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysis. J Invest Dermatol. 2007 Jan; 127(1):196-205. PMID: 16841033.
      Citations: 8     Fields:    Translation:Humans
    368. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006 Jul; 7(1):51-8. PMID: 16879770.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    369. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006 May; 54(5):818-23. PMID: 16635663.
      Citations: 15     Fields:    Translation:Humans
    370. Talpur R, Duvic M. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene. Clin Lymphoma Myeloma. 2006 May; 6(6):488-92. PMID: 16796781.
      Citations: 1     Fields:    Translation:Humans
    371. Ghori F, Polder KD, Pinter-Brown LC, Hoff AO, Gagel RF, Sherman SI, Duvic M. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab. 2006 Jun; 91(6):2205-8. PMID: 16595600.
      Citations: 3     Fields:    Translation:Humans
    372. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin's disease. Int J Dermatol. 2006 Mar; 45(3):251-6. PMID: 16533224.
      Citations: 20     Fields:    Translation:Humans
    373. Remembering Irwin Freedberg. J Invest Dermatol. 2006 Mar; 126(3):519-20. PMID: 16482177.
      Citations:    Fields:    
    374. Barahmani N, de Andrade M, Slusser JP, Zhang Q, Duvic M. Major histocompatibility complex class I chain-related gene A polymorphisms and extended haplotypes are associated with familial alopecia areata. J Invest Dermatol. 2006 Jan; 126(1):74-8. PMID: 16417220.
      Citations: 14     Fields:    Translation:HumansCells
    375. Poonawalla T, Chen W, Duvic M. Mycosis fungoides with tinea pseudoimbricata owing to Trichophyton rubrum infection. J Cutan Med Surg. 2006 Jan-Feb; 10(1):52-6. PMID: 17241575.
      Citations: 1     Fields:    Translation:HumansAnimals
    376. Berthelot C, Cather J, Jones D, Duvic M. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma. 2006 Jan; 6(4):329-32. PMID: 16507211.
      Citations: 5     Fields:    Translation:HumansCells
    377. Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, Clayman GL, Weber RS, Lippman SM, Amos CI, Spitz MR, Wei Q. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31. PMID: 16368944.
      Citations: 14     Fields:    Translation:HumansCells
    378. Polder K, Wang C, Duvic M, Diwan AH, Parks D, Jankov A, Walker PL, Tong AT, Bull J, Dang NH. Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma. Leuk Lymphoma. 2005 Dec; 46(12):1807-11. PMID: 16263585.
      Citations: 6     Fields:    Translation:Humans
    379. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol. 2005 Nov; 125(5):1045-52. PMID: 16297208.
      Citations: 81     Fields:    Translation:HumansCells
    380. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005 Apr; 124(4):741-50. PMID: 15816832.
      Citations: 14     Fields:    Translation:HumansCells
    381. Clayman GL, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005 Feb 01; 23(4):759-65. PMID: 15681519.
      Citations: 58     Fields:    Translation:Humans
    382. Perna AG, Jones DM, Duvic M. Lymphomatoid papulosis from childhood with anaplastic large-cell lymphoma of the small bowel. Clin Lymphoma. 2004 Dec; 5(3):190-3. PMID: 15636695.
      Citations: 2     Fields:    Translation:Humans
    383. Hazarika P, McCarty MF, Prieto VG, George S, Babu D, Koul D, Bar-Eli M, Duvic M. Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res. 2004 Oct 15; 64(20):7361-9. PMID: 15492257.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    384. Whitmore SE. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004 Sep; 51(3):482; author reply 482-3. PMID: 15338005.
      Citations:    Fields:    Translation:HumansCells
    385. Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, Duvic M, King LE, McMichael AJ, Randall VA, Turner ML, Sperling L, Whiting DA, Norris D. Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004 Sep; 51(3):440-7. PMID: 15337988.
      Citations: 77     Fields:    Translation:Humans
    386. Jones D, Ibrahim S, Patel K, Luthra R, Duvic M, Medeiros LJ. Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. Clin Cancer Res. 2004 Aug 15; 10(16):5587-94. PMID: 15328201.
      Citations: 8     Fields:    Translation:Humans
    387. Zhang C, Ni X, Konopleva M, Andreeff M, Duvic M. The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/Sézary syndrome cells. J Invest Dermatol. 2004 Aug; 123(2):380-7. PMID: 15245439.
      Citations: 7     Fields:    Translation:HumansCells
    388. Duvic M, Edelson R. Cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004 Jul; 51(1 Suppl):S43-5. PMID: 15243507.
      Citations: 2     Fields:    Translation:Humans
    389. Garcia-Uribe A, Kehtarnavaz N, Marquez G, Prieto V, Duvic M, Wang LV. Skin cancer detection by spectroscopic oblique-incidence reflectometry: classification and physiological origins. Appl Opt. 2004 May 01; 43(13):2643-50. PMID: 15130003.
      Citations: 19     Fields:    Translation:Humans
    390. Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood. 2004 Aug 01; 104(3):655-8. PMID: 15073032.
      Citations: 21     Fields:    Translation:Humans
    391. Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol. 2004 Apr; 50(4):600-7. PMID: 15034511.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    392. Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004 Jul 15; 104(2):328-35. PMID: 15044256.
      Citations: 32     Fields:    Translation:HumansCells
    393. Tsimberidou AM, Giles F, Romaguera J, Duvic M, Kurzrock R. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer. 2004 Feb 01; 100(3):574-80. PMID: 14745875.
      Citations: 5     Fields:    Translation:Humans
    394. Gaylor ML, Duvic M. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol. 2004 Jan-Feb; 3(1):77-9. PMID: 14964752.
      Citations: 7     Fields:    Translation:Humans
    395. Barahmani N, Whaley K, Duvic M. Alopecia areata after allogeneic bone marrow transplantation from an affected, human leukocyte antigen-matched sibling. J Am Acad Dermatol. 2003 Dec; 49(6):1192. PMID: 14639420.
      Citations: 5     Fields:    Translation:Humans
    396. Shen H, Liu Z, Strom SS, Spitz MR, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Ananthaswamy HN, Wei Q. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4. PMID: 14675203.
      Citations: 12     Fields:    Translation:Humans
    397. Kempf W, Kettelhack N, Duvic M, Burg G. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003 Dec; 17(6):1405-19. PMID: 14710892.
      Citations: 10     Fields:    Translation:Humans
    398. Duvic M, Norris D, Christiano A, Hordinsky M, Price V. Alopecia areata registry: an overview. J Investig Dermatol Symp Proc. 2003 Oct; 8(2):219-21. PMID: 14582678.
      Citations: 4     Fields:    Translation:Humans
    399. Dang NH, Hagemeister FB, Duvic M, Romaguera JE, Younes A, Jones D, Samuels B, Fayad LE, Pro B, Samaniego F, Sarris A, Goy A, McLaughlin P, Tong AT, Walker PL, Tiongson LP, Smith TL, Huh YO, Morimoto C, Rodriguez MA. Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep. 2003 Sep-Oct; 10(5):1513-8. PMID: 12883733.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    400. Hanson M, Hill A, Duvic M. Bexarotene reverses alopecia in cutaneous T-cell lymphoma. Br J Dermatol. 2003 Jul; 149(1):193-6. PMID: 12890219.
      Citations: 2     Fields:    Translation:Humans
    401. Duvic M, Chiao N, Talpur R. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. J Cutan Med Surg. 2003 Jul-Aug; 7(4 Suppl):3-7. PMID: 12958700.
      Citations: 8     Fields:    Translation:Humans
    402. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003 Jul; 49(1):35-49. PMID: 12833006.
      Citations: 7     Fields:    Translation:Humans
    403. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, Lew-Kaya DA, Sefton J, Gibson JR, Walker PS. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003 May; 48(5):760-7. PMID: 12734506.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    404. Clark SH, Duvic M, Prieto VG, Prietol VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol. 2003 Apr; 30(4):279-81. PMID: 12680962.
      Citations: 3     Fields:    Translation:HumansCells
    405. Talpur R, Duvic M. Atypical lymphoid infiltration occurring at the site of a healed varicella zoster infection. Clin Lymphoma. 2003 Mar; 3(4):253-6. PMID: 12672277.
      Citations:    Fields:    Translation:HumansCells
    406. Apisarnthanarax N, Donato M, Körbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003 Mar; 31(6):459-65. PMID: 12665841.
      Citations: 28     Fields:    Translation:Humans
    407. Wei Q, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Strom SS, Wang LE, Guo Z, Qiao Y, Amos CI, Spitz MR, Duvic M. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15. PMID: 12591987.
      Citations: 46     Fields:    Translation:HumansCells
    408. Pielop JA, Brownell I, Duvic M. Mycosis fungoides associated with malignant melanoma and dysplastic nevus syndrome. Int J Dermatol. 2003 Feb; 42(2):116-22. PMID: 12708999.
      Citations: 5     Fields:    Translation:Humans
    409. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003; 206(2):142-7. PMID: 12592082.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    410. Apisarnthanarax N, Ha CS, Duvic M. Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy. Am J Clin Dermatol. 2003; 4(6):429-33. PMID: 12762834.
      Citations: 3     Fields:    Translation:Humans
    411. Singh A, Prieto VG, Czelusta A, McClain KL, Duvic M. Adult Langerhans cell histiocytosis limited to the skin. Dermatology. 2003; 207(2):157-61. PMID: 12920365.
      Citations: 6     Fields:    Translation:Humans
    412. Washington LT, Huh YO, Powers LC, Duvic M, Jones D. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002 Dec 10; 2(1):5. PMID: 12475398.
      Citations: 5     
    413. Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol. 2002 Dec; 47(6):969-70. PMID: 12451394.
      Citations: 1     Fields:    Translation:Humans
    414. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2003 Mar 15; 101(6):2132-6. PMID: 12446446.
      Citations: 13     Fields:    Translation:HumansCells
    415. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002 Nov; 47(5):672-84. PMID: 12399758.
      Citations: 19     Fields:    Translation:Humans
    416. Duan Z, Shen H, Lee JE, Gershenwald JE, Ross MI, Mansfield PF, Duvic M, Strom SS, Spitz MR, Wei Q. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3. PMID: 12376526.
      Citations: 8     Fields:    Translation:HumansCells
    417. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol. 2002 Sep; 29(8):465-72. PMID: 12207740.
      Citations: 5     Fields:    Translation:Humans
    418. Morgan M, Maloney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk Lymphoma. 2002 Jun; 43(6):1297-302. PMID: 12152999.
      Citations: 6     Fields:    Translation:Humans
    419. Kandyil R, Maloney D, Tarrand J, Duvic M. Red nodule on the finger of an immunosuppressed woman. Arch Dermatol. 2002 May; 138(5):689-94. PMID: 12020236.
      Citations:    Fields:    Translation:HumansCells
    420. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res. 2002 May; 8(5):1234-40. PMID: 12006543.
      Citations: 35     Fields:    Translation:HumansCells
    421. Hoefer HF, Chen SH, Duvic MA, Raimer SS. Alopecia, hypohidrosis, and ulcerations in a man: mycosis fungoides. Arch Dermatol. 2002 Apr; 138(4):527-32. PMID: 11939819.
      Citations: 1     Fields:    Translation:Humans
    422. Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma. 2002 Mar; 2(4):222-8. PMID: 11970761.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    423. Breneman D, Duvic M, Kuzel T, Yocum R, Truglia J, Stevens VJ. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol. 2002 Mar; 138(3):325-32. PMID: 11902983.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    424. Barahmani N, Barahamani N, de Andrade M, Slusser J, Zhang Q, Duvic M. Interleukin-1 receptor antagonist allele 2 and familial alopecia areata. J Invest Dermatol. 2002 Feb; 118(2):335-7. PMID: 11841553.
      Citations: 5     Fields:    Translation:Humans
    425. Talpur R, Apisarnthanarax N, Ward S, Duvic M. Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). Leuk Lymphoma. 2002 Jan; 43(1):121-6. PMID: 11908715.
      Citations: 9     Fields:    Translation:Humans
    426. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002; 3(3):193-215. PMID: 11978140.
      Citations: 8     Fields:    Translation:Humans
    427. Vonderheid EC, Bernengo MG, Burg G, Duvic M, Heald P, Laroche L, Olsen E, Pittelkow M, Russell-Jones R, Takigawa M, Willemze R. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002 Jan; 46(1):95-106. PMID: 11756953.
      Citations: 46     Fields:    Translation:Humans
    428. Breuer-McHam J, Simpson E, Dougherty I, Bonkobara M, Ariizumi K, Lewis DE, Dawson DB, Duvic M, Cruz PD. Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents. Photochem Photobiol. 2001 Dec; 74(6):805-10. PMID: 11783936.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    429. Apisarnthanarax N, Duvic M. Therapy options in cutaneous T-cell lymphoma. Expert Rev Anticancer Ther. 2001 Oct; 1(3):403-20. PMID: 12113107.
      Citations:    Fields:    Translation:Humans
    430. Apisarnthanarax N, Duvic M. Cutaneous T-cell lymphoma. New immunomodulators. Dermatol Clin. 2001 Oct; 19(4):737-48. PMID: 11705358.
      Citations:    Fields:    Translation:Humans
    431. Sober AJ, Chuang TY, Duvic M, Farmer ER, Grichnik JM, Halpern AC, Ho V, Holloway V, Hood AF, Johnson TM, Lowery BJ. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol. 2001 Oct; 45(4):579-86. PMID: 11568750.
      Citations: 11     Fields:    Translation:Humans
    432. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res. 2001 Sep; 7(9):2682-92. PMID: 11555580.
      Citations: 15     Fields:    Translation:HumansCells
    433. Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol. 2001 Aug; 137(8):1071-2. PMID: 11493100.
      Citations: 7     Fields:    Translation:Humans
    434. Hwong H, Nichols T, Duvic M. "Invisible" mycosis fungoides? J Am Acad Dermatol. 2001 Aug; 45(2):318. PMID: 11464202.
      Citations: 1     Fields:    Translation:Humans
    435. Duvic M, Olsen EA, Omura GA, Maize JC, Vonderheid EC, Elmets CA, Shupack JL, Demierre MF, Kuzel TM, Sanders DY. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001 Jun; 44(6):940-7. PMID: 11369904.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    436. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001 Jun; 115(6):885-92. PMID: 11392886.
      Citations: 29     Fields:    Translation:HumansCells
    437. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 May 01; 19(9):2456-71. PMID: 11331325.
      Citations: 90     Fields:    Translation:HumansCTClinical Trials
    438. Duvic M, Nelson A, de Andrade M. The genetics of alopecia areata. Clin Dermatol. 2001 Mar-Apr; 19(2):135-9. PMID: 11397591.
      Citations: 1     Fields:    Translation:HumansAnimals
    439. Duvic M. Current treatment of Cutaneous T-Cell Lymphoma. Dermatol Online J. 2001 Feb; 7(1):3. PMID: 11328624.
      Citations: 2     Fields:    Translation:Humans
    440. Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001 Jan 15; 19(2):376-88. PMID: 11208829.
      Citations: 102     Fields:    Translation:HumansCTClinical Trials
    441. Sarris AH, Braunschweig I, Medeiros LJ, Duvic M, Ha CS, Rodriguez MA, Hagemeister FB, McLaughlin P, Romaguera J, Cox J, Cabanillas F. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001 Jan 15; 19(2):398-405. PMID: 11208831.
      Citations: 2     Fields:    Translation:Humans
    442. McMullan DM, Radovaneevic B, Jackow CM, Frazier OH, Duvic M. Cutaneous T-cell lymphoma in a cardiac transplant recipient. Tex Heart Inst J. 2001; 28(3):203-7. PMID: 11678256.
      Citations:    Fields:    Translation:Humans
    443. McMillen R, Duvic M. Alopecia areata occurring in sisters after administration of rifampicin. J Am Acad Dermatol. 2001 Jan; 44(1):142-3. PMID: 11148494.
      Citations: 1     Fields:    Translation:Humans
    444. Lee J, Apisarnthanarax N, Jordon RE, Duvic M. Cryofibrinogenemia in a patient with B-cell lymphoma. Clin Lymphoma. 2000 Dec; 1(3):234-7; discussion 238-9. PMID: 11707837.
      Citations:    Fields:    Translation:Humans
    445. Duvic M. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin Lymphoma. 2000 Nov; 1 Suppl 1:S51-5. PMID: 11707865.
      Citations: 3     Fields:    Translation:Humans
    446. Breuer-McHam JN, Ledbetter LS, Sarris AH, Duvic M. Cytokine expression patterns distinguish HIV associated skin diseases. Exp Dermatol. 2000 Oct; 9(5):341-50. PMID: 11016855.
      Citations: 2     Fields:    Translation:HumansCells
    447. Duvic M, Feasel AM, Schwartz CA, Cather JC. Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity. Clin Lymphoma. 2000 Sep; 1(2):141-5. PMID: 11707823.
      Citations: 2     Fields:    Translation:HumansCells
    448. Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RA, Robinson NA, Deucher A, Eckert RL, Nagpal S. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res. 2000 Aug; 6(8):3249-59. PMID: 10955811.
      Citations: 19     Fields:    Translation:Humans
    449. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000 Aug; 43(2 Pt 1):281-5. PMID: 10906652.
      Citations: 22     Fields:    Translation:Humans
    450. Duvic M, Cather JC. Emerging new therapies for cutaneous T-cell lymphoma. Dermatol Clin. 2000 Jan; 18(1):147-56. PMID: 10626120.
      Citations: 6     Fields:    Translation:Humans
    451. Cather JC, Nelson BR, Duvic M. Malignant melanoma--clinical diagnostic techniques. Cutis. 1999 Dec; 64(6):379-88. PMID: 10626101.
      Citations:    Fields:    Translation:Humans
    452. de Andrade M, Jackow CM, Dahm N, Hordinsky M, Reveille JD, Duvic M. Alopecia areata in families: association with the HLA locus. J Investig Dermatol Symp Proc. 1999 Dec; 4(3):220-3. PMID: 10674370.
      Citations: 10     Fields:    Translation:Humans
    453. Kurzrock R, Pilat S, Duvic M. Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol. 1999 Oct; 17(10):3117-21. PMID: 10506607.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    454. Hazarika P, Dham N, Patel P, Cho M, Weidner D, Goldsmith L, Duvic M. Flotillin 2 is distinct from epidermal surface antigen (ESA) and is associated with filopodia formation. J Cell Biochem. 1999 Oct 01; 75(1):147-59. PMID: 10462713.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    455. Stevens SR, Bowen GM, Duvic M, King LE, Knobler R, Lim HW, Margolis D, Parry EJ, Rook AH, Stricklin GP, Suchin KR, Tharp MD, Vonderheid E, Zic JA. Effectiveness of photopheresis in Sézary syndrome. Arch Dermatol. 1999 Aug; 135(8):995-7. PMID: 10456362.
      Citations: 1     Fields:    Translation:Humans
    456. Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 1999 Jun; 40(6 Pt 1):914-24. PMID: 10365922.
      Citations: 17     Fields:    Translation:Humans
    457. Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999 Apr 08; 340(14):1075-9. PMID: 10194237.
      Citations: 41     Fields:    Translation:HumansCells
    458. Sarris AH, Kliche KO, Pethambaram P, Preti A, Tucker S, Jackow C, Messina O, Pugh W, Hagemeister FB, McLaughlin P, Rodriguez MA, Romaguera J, Fritsche H, Witzig T, Duvic M, Andreeff M, Cabanillas F. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Ann Oncol. 1999 Apr; 10(4):433-40. PMID: 10370786.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    459. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol. 1999 Jan; 6(1):79-84. PMID: 9874668.
      Citations: 17     Fields:    Translation:HumansCells
    460. Breuer-McHam J, Marshall G, Adu-Oppong A, Goller M, Mays S, Berger T, Lewis DE, Duvic M. Alterations in HIV expression in AIDS patients with psoriasis or pruritus treated with phototherapy. J Am Acad Dermatol. 1999 Jan; 40(1):48-60. PMID: 9922012.
      Citations: 1     Fields:    Translation:HumansCells
    461. DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14811-5. PMID: 9843971.
      Citations: 45     Fields:    Translation:HumansAnimalsCells
    462. Konstantinova NV, Lemak NA, Duvic M. Nerve growth factor in normal and psoriatic skin equivalent models. Arch Dermatol Res. 1998 Nov; 290(11):610-4. PMID: 9860281.
      Citations: 1     Fields:    Translation:HumansCells
    463. Cather JC, Farmer A, Jackow C, Manning JT, Shin DM, Duvic M. Unusual presentation of mycosis fungoides as pigmented purpura with malignant thymoma. J Am Acad Dermatol. 1998 Nov; 39(5 Pt 2):858-63. PMID: 9810916.
      Citations: 1     Fields:    Translation:Humans
    464. Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol. 1998 Oct; 39(4 Pt 2):S134-8. PMID: 9777791.
      Citations: 1     Fields:    Translation:Humans
    465. Duvic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol. 1998 Oct; 39(4 Pt 2):S129-33. PMID: 9777790.
      Citations: 8     Fields:    Translation:HumansCells
    466. Peterson SR, Talpur R, Duvic M. Antinuclear antibody seropositivity in patients with cutaneous T-cell lymphoma. J Am Acad Dermatol. 1998 Sep; 39(3):434-8. PMID: 9738778.
      Citations:    Fields:    Translation:Humans
    467. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998 Aug 15; 92(4):1150-9. PMID: 9694702.
      Citations: 26     Fields:    Translation:HumansCells
    468. Duvic M, Cather J, Maize J, Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol. 1998 May; 58(1):87-90. PMID: 9590158.
      Citations: 10     Fields:    Translation:Humans
    469. Jackow C, Puffer N, Hordinsky M, Nelson J, Tarrand J, Duvic M. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol. 1998 Mar; 38(3):418-25. PMID: 9520023.
      Citations: 23     Fields:    Translation:Humans
    470. Cather JC, Jackow C, Yegge J, Hagemeister F, Duvic M. Mycosis fungoides with focal segmental glomerular sclerosis and nephrotic syndrome. J Am Acad Dermatol. 1998 Feb; 38(2 Pt 2):301-5. PMID: 9486702.
      Citations: 1     Fields:    Translation:Humans
    471. Duvic M. Pharmacologic profile of tazarotene. Cutis. 1998 Feb; 61(2 Suppl):22-6. PMID: 9787988.
      Citations: 1     Fields:    Translation:HumansAnimals
    472. Breuer-McHam JN, Marshall GD, Lewis DE, Duvic M. Distinct serum cytokines in AIDS-related skin diseases. Viral Immunol. 1998; 11(4):215-20. PMID: 10189188.
      Citations: 3     Fields:    Translation:Humans
    473. Smith KJ, Yeager J, Skelton HG. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol. 1997 Nov; 37(5 Pt 1):806-8. PMID: 9366841.
      Citations: 7     Fields:    Translation:HumansCells
    474. Byers PH, Duvic M, Atkinson M, Robinow M, Smith LT, Krane SM, Greally MT, Ludman M, Matalon R, Pauker S, Quanbeck D, Schwarze U. Ehlers-Danlos syndrome type VIIA and VIIB result from splice-junction mutations or genomic deletions that involve exon 6 in the COL1A1 and COL1A2 genes of type I collagen. Am J Med Genet. 1997 Oct 03; 72(1):94-105. PMID: 9295084.
      Citations: 26     Fields:    Translation:HumansCells
    475. Duvic M. Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis. Expert Opin Investig Drugs. 1997 Oct; 6(10):1537-51. PMID: 15989518.
      Citations: 1     Fields:    
    476. Weitzul S, Duvic M. HIV-related psoriasis and Reiter's syndrome. Semin Cutan Med Surg. 1997 Sep; 16(3):213-8. PMID: 9300632.
      Citations: 2     Fields:    Translation:Humans
    477. Zackheim HS, Kashani-Sabet M. Response rates in photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1997 Aug; 37(2 Pt 1):287-8. PMID: 9270526.
      Citations:    Fields:    Translation:Humans
    478. Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997 Aug; 37(2 Pt 3):S18-24. PMID: 9270552.
      Citations: 15     Fields:    Translation:HumansCells
    479. Musette P, Bachelez H. Cutaneous T-cell lymphomas and bacterial superantigens. Blood. 1997 Jul 01; 90(1):472-3. PMID: 9207487.
      Citations:    Fields:    Translation:HumansCells
    480. Nagpal S, Patel S, Jacobe H, DiSepio D, Ghosn C, Malhotra M, Teng M, Duvic M, Chandraratna RA. Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin. J Invest Dermatol. 1997 Jul; 109(1):91-5. PMID: 9204961.
      Citations: 83     Fields:    Translation:HumansCells
    481. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, Jorizzo JL, Shmunes E, Tschen EH, Lew-Kaya DA, Lue JC, Sefton J, Gibson JR, Chandraratna RA. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997 Jul; 37(1):85-92. PMID: 9216528.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    482. Cohen PR, Ulmer R, Theriault A, Leigh IM, Duvic M. Epidermolytic acanthomas: clinical characteristics and immunohistochemical features. Am J Dermatopathol. 1997 Jun; 19(3):232-41. PMID: 9185908.
      Citations: 8     Fields:    Translation:Humans
    483. Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Reiss M, Karasavvas N, Zelenetz AD, Pugh W, Cabanillas F, Deisseroth AB, Duvic M. Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomas. Clin Cancer Res. 1997 Feb; 3(2):169-77. PMID: 9815669.
      Citations: 2     Fields:    Translation:HumansCells
    484. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997 Jan 01; 89(1):32-40. PMID: 8978274.
      Citations: 48     Fields:    Translation:HumansCells
    485. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Ann Oncol. 1997; 8 Suppl 2:59-63. PMID: 9209643.
      Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
    486. Goller MM, Cohen PR, Duvic M. Lichen amyloidosis presenting as a papular pruritus syndrome in a human-immunodeficiency-virus-infected man. Dermatology. 1997; 194(1):62-4. PMID: 9031795.
      Citations:    Fields:    Translation:Humans
    487. Davis DA, Cohen PR, McNeese MD, Duvic M. Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: radiation port scleroderma. J Am Acad Dermatol. 1996 Dec; 35(6):923-7. PMID: 8959951.
      Citations: 14     Fields:    Translation:Humans
    488. Nagpal S, Thacher SM, Patel S, Friant S, Malhotra M, Shafer J, Krasinski G, Asano AT, Teng M, Duvic M, Chandraratna RA. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996 Dec; 7(12):1783-91. PMID: 8959347.
      Citations: 10     Fields:    Translation:HumansCells
    489. Sarris AH, Daliani D, Ulmer R, Crow M, Broxmeyer HE, Pugh W, Reiss M, Cabanillas F, Deisseroth AB, Duvic M. Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas. Leuk Lymphoma. 1996 Dec; 24(1-2):103-10. PMID: 9049966.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    490. Duvic M, Hester JP, Lemak NA. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996 Oct; 35(4):573-9. PMID: 8859287.
      Citations: 8     Fields:    Translation:Humans
    491. Konstantinova NV, Duong DM, Remenyik E, Hazarika P, Chuang A, Duvic M. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol. 1996 Oct; 107(4):615-21. PMID: 8823370.
      Citations: 7     Fields:    Translation:HumansCells
    492. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1*03 class II alleles are associated with cutaneous T-cell lymphoma. J Invest Dermatol. 1996 Sep; 107(3):373-6. PMID: 8751973.
      Citations: 16     Fields:    Translation:Humans
    493. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, Dimopoulos MA, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. Blood. 1996 Sep 01; 88(5):1771-9. PMID: 8781434.
      Citations: 11     Fields:    Translation:HumansCells
    494. Morris LF, Lemak NA, Arnett FC, Jordon RE, Duvic M. Systemic lupus erythematosus diagnosed during interferon alfa therapy. South Med J. 1996 Aug; 89(8):810-4. PMID: 8701383.
      Citations: 4     Fields:    Translation:Humans
    495. Asadullah K, Haeussler A, Sterry W, Döcke WD, Volk HD. Interferon gamma and tumor necrosis factor alpha mRNA expression in mycosis fungoides progression. Blood. 1996 Jul 15; 88(2):757-8. PMID: 8695829.
      Citations: 4     Fields:    Translation:Humans
    496. Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, Trancik RJ, Bandstra BA, Compton LD. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996 Jul; 35(1):74-8. PMID: 8682968.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    497. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 1996 Jun; 34(6):1022-9. PMID: 8647968.
      Citations: 10     Fields:    Translation:Humans
    498. Jackson M, Thomson KE, Laker R, Norval M, Hunter JA, McKenzie RC. Lack of induction of IL-10 expression in human keratinocytes. J Invest Dermatol. 1996 Jun; 106(6):1329-31. PMID: 8752679.
      Citations:    Fields:    Translation:HumansCells
    499. Milewicz DM, Byers PH, Reveille J, Hughes AL, Duvic M. A dimorphic Alu Sb-like insertion in COL3A1 is ethnic-specific. J Mol Evol. 1996 Feb; 42(2):117-23. PMID: 8919863.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    500. Nagpal S, Patel S, Asano AT, Johnson AT, Duvic M, Chandraratna RA. Tazarotene-induced gene 1 (TIG1), a novel retinoic acid receptor-responsive gene in skin. J Invest Dermatol. 1996 Feb; 106(2):269-74. PMID: 8601727.
      Citations: 30     Fields:    Translation:HumansCells
    501. Wakem P, Ikeda S, Haake A, Polakowska R, Ewing N, Sarret Y, Duvic M, Berg D, Bassett A, Kennedy JL, Tuskis A, Epstein EH, Goldsmith LA. Localization of the Darier disease gene to a 2-cM portion of 12q23-24.1. J Invest Dermatol. 1996 Feb; 106(2):365-7. PMID: 8601743.
      Citations: 1     Fields:    Translation:HumansCells
    502. Stricker RB, Goldberg B. Zidovudine and psoriasis. J Am Acad Dermatol. 1996 Jan; 34(1):152. PMID: 8543688.
      Citations:    Fields:    Translation:Humans
    503. Sendagorta E, Ledo A. Sézary syndrome in association with silicone breast implant. J Am Acad Dermatol. 1995 Dec; 33(6):1060-1. PMID: 7490360.
      Citations: 6     Fields:    Translation:Humans
    504. Westerhof W, Boersma B. The minigrafting test for vitiligo: detection of stable lesions for melanocyte transplantation. J Am Acad Dermatol. 1995 Dec; 33(6):1061-2. PMID: 7490361.
      Citations: 4     Fields:    Translation:HumansCells
    505. Friss AB, Cohen PR, Bruce S, Duvic M. Chronic cutaneous lupus erythematosus mimicking mycosis fungoides. J Am Acad Dermatol. 1995 Nov; 33(5 Pt 2):891-5. PMID: 7593804.
      Citations: 1     Fields:    Translation:Humans
    506. Sterenborg NJ, Thomsen S, Jacques SL, Duvic M, Motamedi M, Wagner RF. In vivo fluorescence spectroscopy and imaging of human skin tumors. Dermatol Surg. 1995 Sep; 21(9):821-2. PMID: 7655806.
      Citations: 2     Fields:    Translation:Humans
    507. Sarris AH, Esgleyes-Ribot T, Crow M, Broxmeyer HE, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M. Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? Blood. 1995 Jul 15; 86(2):651-8. PMID: 7605995.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    508. Duvic M, Moore D, Menter A, Vonderheid EC. Cutaneous T-cell lymphoma in association with silicone breast implants. J Am Acad Dermatol. 1995 Jun; 32(6):939-42. PMID: 7751462.
      Citations: 17     Fields:    Translation:Humans
    509. Cho YJ, Chema D, Moskow JJ, Cho M, Schroeder WT, Overbeek P, Buchberg AM, Duvic M. Epidermal surface antigen (MS17S1) is highly conserved between mouse and human. Genomics. 1995 May 20; 27(2):251-8. PMID: 7557989.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    510. Duvic M, Welsh EA, Jackow C, Papadopoulos E, Reveille JD, Amos C. Analysis of HLA-D locus alleles in alopecia areata patients and families. J Invest Dermatol. 1995 May; 104(5 Suppl):5S-6S. PMID: 7738397.
      Citations: 2     Fields:    Translation:Humans
    511. Cho M, Cohen PR, Duvic M. Vitiligo and alopecia areata in patients with human immunodeficiency virus infection. South Med J. 1995 Apr; 88(4):489-91. PMID: 7716609.
      Citations: 3     Fields: